Focused On-demand Library for Alpha-2,8-sialyltransferase 8F

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

Sialyltransferase 8F; Sialyltransferase St8Sia VI

Alternative UPACC:

P61647; B0YJ97; B9EH72; Q5VZH4


Alpha-2,8-sialyltransferase 8F, also known as Sialyltransferase St8Sia VI, is an enzyme that catalyzes the transfer of sialic acid to glycan substrates. It exhibits a preference for O-glycans over N-glycans or glycolipids, with the minimal acceptor substrate being the NeuAc-alpha-2,3(6)-Gal sequence. This specificity plays a crucial role in the biosynthesis of complex carbohydrate structures.

Therapeutic significance:

Understanding the role of Alpha-2,8-sialyltransferase 8F could open doors to potential therapeutic strategies. Its involvement in the synthesis of sialoglycans, which are key components of cellular communication and molecular recognition processes, highlights its potential as a target for therapeutic intervention.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.